Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00866736Phase 2Completed

A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

Role: lead

NCT01342679Phase 2Completed

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

Role: lead

NCT01887561Phase 2Unknown

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Role: lead

NCT01464411Unknown

Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan

Role: lead

All 4 trials loaded